• Biotin-HPDP Workflows for PPT1 Research

  2026-08-13

  Biotin-HPDP adds a reversible, thiol-directed layer to PPT1 and neurodegeneration research, enabling biochemical analysis alongside receptor, cognition, and network measurements. Its disulfide-linked biotin handle supports S-nitrosylation studies, affinity enrichment, and controlled release from streptavidin workflows.

• Alternariol (AOH): Applied Research Workflows

  2026-08-13

  Build stronger mycotoxin, hepatotoxicity, CYP, and apoptosis studies with Alternariol (AOH), using controlled exposure, orthogonal readouts, and model-specific interpretation. The workflow connects molecular metabolism to hepatic stellate-cell activation while showing where comparative toxin testing and CotA detoxification fit—and where they remain exploratory.

• HyperScribe T7 High Yield Cy5 RNA Labeling Kit Guide

  2026-08-12

  Build bright, reproducible fluorescent RNA probes for in situ hybridization and Northern blot workflows with tunable Cy5-UTP incorporation. This practical guide connects probe-quality controls to modern mRNA-delivery studies, including ROS-responsive lipid nanoparticle assays, without confusing analytical labeling with therapeutic function.

• Radiotherapy, PD-1 and TIGIT Blockade in Tumor Immunity

  2026-08-12

  The 2025 Cancer Letters study shows that radiotherapy combined with PD-1 and TIGIT blockade can extend tumor control beyond the irradiated site and establish durable CD8+ T-cell memory. Its integrated mouse-model, single-cell, cytokine, and adoptive-transfer experiments identify activated M1 macrophages and CD8+ T cells as key components of this systemic response.

• Glioma Organoids Preserve the Tumor Microenvironment

  2026-08-11

  The reference study introduces GlioME, a patient-derived glioma organoid model designed to retain tumor-associated cellular interactions and resident immune cells. Integrated transcriptomic, genomic, epigenetic, immunofluorescence, and flow-cytometry analyses support its use as a context-aware platform for personalized drug screening, while also defining important limits for interpretation and transferability.

• From SA-β-Gal to Senolytic Translation

  2026-08-11

  SA-β-Gal is more than a blue stain: it is a practical entry point for connecting senescent-cell biology with senolytic drug discovery. This thought-leadership guide explains how to use the Cell Senescence β-Galactosidase Staining Kit to strengthen experimental controls, interpret mechanistic findings, and build a more translational cellular senescence assay.

• CD38 CAR Binder Structure and Affinity Tuning

  2026-08-10

  The reference study structurally compares the CD38-targeting CAR binders RP02 and 028, showing that they recognize different CD38 surfaces and produce distinct effects on enzymatic activity. Its affinity-attenuated 028R103G variant reduced CAR-T fratricide while preserving cytotoxicity against CD38-positive tumor cells, providing a structure-guided framework for balancing potency and selectivity.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody Workflow

  2026-08-09

  Build sensitive adrenal-cell imaging, flow cytometry, and western blot workflows around a Cy3 Goat Anti-Mouse IgG (H+L) Antibody that amplifies mouse primary-antibody signals. The workflow translates renalase–PMCA4b findings into practical controls, assay choices, and troubleshooting steps without confusing literature results with product validation.

• Schwartz 2022: Better In Vitro Cancer Drug Responses

  2026-08-08

  Hannah R. Schwartz’s dissertation clarifies why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a framework for distinguishing growth inhibition from actual cell killing, improving experimental design and interpretation across cancer drug studies.

• Necrostatin 2: A Cell Death Assay Framework

  2026-08-07

  Necrostatin 2 (Nec-2) enables targeted investigation of necroptosis inhibition and RIPK2 signaling. This article presents an assay-first framework that separates programmed necrotic cell death from ferroptotic membrane failure and improves interpretation in ischemic stroke research.

• AO/PI Double Staining Kit: Practical Guide for Cell Viabilit

  2026-08-07

  The AO/PI Double Staining Kit enables rapid, fluorescence-based discrimination of viable, apoptotic, and necrotic cells, providing researchers with actionable cell viability and death-state data. It is best suited for workflows requiring clear, reproducible differentiation between live and dead cell populations using microscopy or flow cytometry. This kit is not recommended for non-fluorescent viability assays or settings that require non-destructive live-cell analysis over extended periods.

• GDC-0068 (RG7440): Selective Pan-AKT Inhibitor for PI3K/Akt/

  2026-08-06

  GDC-0068 (RG7440) is a potent, isoform-selective ATP-competitive Akt inhibitor that enables precise interrogation of the PI3K/Akt/mTOR pathway. It demonstrates high efficacy in tumor models with PTEN loss or PI3K mutations, inducing cell cycle arrest and apoptosis. APExBIO supplies this benchmark compound for research applications requiring robust pathway control.

• Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagon

  2026-08-06

  Dantrolene sodium salt empowers researchers to control intracellular calcium release with nanomolar precision, enabling reproducible genome editing and disease modeling. This guide translates bench breakthroughs into actionable protocols and troubleshooting insights for RyR antagonism, as validated in high-impact studies.

• FXR-KLF11 Axis: CDCA Suppresses JAK2/STAT3 in CI-AKI Models

  2026-08-05

  This study demonstrates that Chenodeoxycholic Acid (CDCA) activates FXR to upregulate KLF11, suppressing the JAK2/STAT3 pathway and protecting against contrast-induced acute kidney injury (CI-AKI). The findings establish the FXR–KLF11 axis as a critical mechanism in renal protection, offering new directions for nuclear receptor signaling and kidney injury research.

• KX2-391 Dihydrochloride: Translational Advances in Metastati

  2026-08-05

  Explore the multidimensional utility of KX2-391 dihydrochloride as a dual Src kinase and tubulin inhibitor for advanced oncology and HBV research. This article uniquely dissects its role in translational metastasis blockade, integrating recent mechanistic breakthroughs and optimized protocol guidance.

3599 records 3/240 page Previous Next 12345 下5页 Last page